Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor microbial burden drives immune responses through regulation of Interferon signaling.

Cancer discovery·2026
Same author

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

iScience·2026
Same author

A pan-cancer single-cell analysis of intratumoral copy number diversity and evolution.

Cancer discovery·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Ecotypes of triple-negative breast cancer in response to chemotherapy.

Nature·2026
Same author

PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Dec 15, 2025

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.7K

Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing.

Naveen Ramesh1,2, Emi Sei1, Pei Ching Tsai3

  • 1Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Genome Biology
|July 8, 2020
PubMed
Summary

We developed a non-invasive plasma DNA sequencing method to track prostate cancer genome evolution during therapy. This approach identifies resistant clones, offering new insights into treatment response and cancer evolution.

Keywords:
Liquid biopsiesNon-invasiveTumor evolution

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Related Experiment Videos

Last Updated: Dec 15, 2025

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Area of Science:

  • Genomics
  • Cancer Research
  • Molecular Biology

Background:

  • Studying cancer genome evolution during therapy is challenging using human tissue samples.
  • Archival cryostored plasma samples offer a potential source for longitudinal genomic analysis.
  • Prostate cancer patients often present difficulties in collecting serial tissue biopsies from metastatic sites.

Purpose of the Study:

  • To develop an unbiased whole-genome sequencing approach for plasma DNA.
  • To concurrently measure genomic copy number and exome mutations from plasma DNA.
  • To investigate genome evolution in response to therapy in prostate cancer patients non-invasively.

Main Methods:

  • Developed an unbiased whole-genome plasma DNA sequencing approach.
  • Applied the method to archival plasma samples from prostate cancer patients.
  • Performed deep-exome sequencing and genomic copy number profiling on plasma and matched tissue samples.

Main Results:

  • Identified clinical correlations between aneuploid plasma DNA profiles and poor survival.
  • Demonstrated high concordance of genomic alterations between plasma DNA and metastatic tissue.
  • Revealed clonal dynamics and genome evolution in response to therapy using longitudinal plasma samples.

Conclusions:

  • The developed approach enables non-invasive delineation of clonal dynamics in prostate cancer.
  • Identified therapy-induced subclone expansion and mutations associated with resistance.
  • Plasma DNA sequencing provides a representative and evolutionary view of tissue alterations during cancer treatment.